Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis

Brian L. Erstad, Jeffrey F. Barletta

Research output: Contribution to journalReview articlepeer-review

Abstract

Medications used for supportive care or prophylaxis constitute a significant portion of drug utilization in the intensive care unit. Evidence-based guidelines are available for many aspects of supportive care but drug doses listed are typically for patients with normal body habitus and not morbid obesity. Failure to account for the pharmacokinetic changes that occur with obesity can lead to an incorrect dose and treatment failure or toxicity. This paper is intended to help clinicians design initial dosing regimens in critically ill obese patients for medications commonly used for hemodynamic support or prophylaxis. A detailed literature search of medications used for supportive care or prophylaxis listed in practice guidelines was conducted with an emphasis on obesity, pharmacokinetics and dosing. Relevant manuscripts were reviewed and strategies for dosing are provided. For medications used for hemodynamic support, a similar strategy can be used as in non-obese patients. Similarly, medications for stress ulcer prophylaxis do not need to be adjusted. Anticoagulants for venous thromboembolism prophylaxis, on the other hand, require an individualized approach where higher doses are necessary.

Original languageEnglish (US)
Article number77
JournalCritical Care
Volume25
Issue number1
DOIs
StatePublished - Dec 2021

Keywords

  • Critical illness
  • Drug dosing
  • Obesity
  • Pharmacokinetics

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis'. Together they form a unique fingerprint.

Cite this